News
06-02-2019, 11:42 PM
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
More... (https://www.news-medical.net/news/20190603/Targeted-therapy-plus-hormone-therapy-improves-survival-in-premenopausal-patients-with-advanced-HR2b-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20190603/Targeted-therapy-plus-hormone-therapy-improves-survival-in-premenopausal-patients-with-advanced-HR2b-breast-cancer.aspx)